stockrow
Friday 6 November 2026
Export QGEN’s income statement to Excel — free account
QIAGEN N.V.
QGEN Healthcare Diagnostics & Research
QIAGEN N.V.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 5.65% from fiscal 2024.
- Revenue
- +0.28%
- EPS
- +7.94%
- Free cash flow
- +30.5%
- Total debt
- +13.8%
Quarter to June 2026, against a year earlier
50.88
0.05
+0.10%
Follow QGEN
Alert me
QIAGEN N.V. (QGEN) Revenue
QIAGEN N.V.'s revenue for fiscal 2025 was $2.1B, up 5.65% from $2.0B in fiscal 2024. Over the twelve months to 30 June 2026 it was $2.1B. Over the past ten years it has ranged from $1.3B (fiscal 2015) to $2.3B (fiscal 2021); the current reading is higher than 82% of that period. QIAGEN N.V. ranks 17th of 47 Diagnostics & Research companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $2.1B | 5.65% |
| FY2024 | $2.0B | 0.66% |
| FY2023 | $2.0B | (8.23%) |
| FY2022 | $2.1B | (4.89%) |
| FY2021 | $2.3B | 20.39% |
| FY2020 | $1.9B | 22.53% |
| FY2019 | $1.5B | 1.64% |
| FY2018 | $1.5B | 5.95% |
| FY2017 | $1.4B | 5.95% |
| FY2016 | $1.3B | 4.45% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $535.0M | 8.68% |
| Mar 2026 | $492.3M | (8.90%) |
| Dec 2025 | $540.4M | 1.47% |
| Sep 2025 | $532.6M | (0.18%) |
| 42 more quarters | Free account |
Against its own ten years
Low $1.3B
High $2.3B
Ten-year median
$1.9B
Current reading's percentile
82
Revenue against peers
| Company | Revenue |
|---|---|
| ICLR ICON PLC compare | $8.2B |
| CRL Charles River Laboratories International, Inc. compare | $4.0B |
| RVTY Revvity Inc. compare | $2.9B |
| MEDP Medpace Holdings, Inc. compare | $2.8B |
| RDNT RadNet, Inc. compare | $2.3B |
| QGEN QIAGEN N.V. | $2.1B |
| GH Guardant Health, Inc. compare | $1.3B |
| BLLN BillionToOne, Inc. compare | $436.9M |
| GRAL GRAIL, Inc. compare | $166.6M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on QGEN
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement